The Epoch Times
The Epoch Times
Focus

Bristol-Myers

Business
Business
|
Reuters

Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal

Jun 04, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal
Jun 04
|
FacebookXTruthGettrLinkedInTelegramEmail
Health News
Health News
|
Reuters

Bristol Myers Drug Wins First US Approval for Graft Versus Host Disease Prevention

Dec 15, 2021
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Bristol Myers Drug Wins First US Approval for Graft Versus Host Disease Prevention
Dec 15
|
FacebookXTruthGettrLinkedInTelegramEmail
Business
Business
|
Reuters

Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal

Jun 04, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal
Jun 04
|
FacebookXTruthGettrLinkedInTelegramEmail
Health News
Health News
|
Reuters

Bristol Myers Drug Wins First US Approval for Graft Versus Host Disease Prevention

Dec 15, 2021
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Bristol Myers Drug Wins First US Approval for Graft Versus Host Disease Prevention
Dec 15
|
FacebookXTruthGettrLinkedInTelegramEmail
home-iconepochtv-iconhealth-iconbright-iconepochfun-icon
The Epoch Times
To ensure we reach the high standards of reliability and neutrality that you expect from us, we are engaging with Ad Fontes Media to analyze our content. If you find an article you think falls short of the standard, please submit the link through this form.
Copyright © 2000 - 2025 The Epoch Times Association Inc. All Rights Reserved.